MedTrace Logo

Gene Expression Objective Definition of Early Sepsis In Children

NCT06231862 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-01-30

No results posted yet for this study

Summary

GEODESIC is a prospective descriptive cohort investigation that will examine the generalizability of the novel host gene expression biomarkers, SeptiCyteTM LAB, SeptiCyteTM VIRUS, SeptiCyteTM BACT, and SeptiCyteTM TRIAGE (collectively 18 genes or SeptiCyteTM LVBT) and SeptiCyteTM RAPID, for differentiating children with bacterial sepsis, versus severe viral illness, versus non-infectious related systemic inflammatory response syndrome.

Conditions

  • Sepsis
  • Non-Infectious Systemic Inflammatory Response Syndrome

Interventions

DIAGNOSTIC_TEST

SeptiCyte (various)

mRNA expression scores

Sponsors & Collaborators

  • Immunexpress

    collaborator INDUSTRY

  • Seattle Children's Hospital

    lead OTHER

Principal Investigators

  • Jerry J Zimmerman, MD, PhD · Seattle Children's Research Center

Eligibility

Min Age
1 Month
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2023-03-01
Completion
2023-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06231862 on ClinicalTrials.gov